Can enasidenib cure leukemia?

Ensidipine (Enasidenib) is a promising drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). Through preclinical and clinical evaluations, ensidipine has shown significant activity in patients with IDH2 mutations. Although generally well tolerated, careful monitoring is required throughout treatment.

Although ensidipine can significantly improve patient survival and reduce the risk of disease progression, it is not considered a "cure" drug for leukemia. There is currently no drug or treatment to cure leukemia. Leukemia is a complex disease whose development and treatment are affected by many factors, and life expectancy depends on a person's age, the type of leukemia and other factorsincluding the characteristics of the cancer cells, the patient's overall health and other genetic and environmental factors. Ensidipine is often used as part of a maintenance regimen to control disease recurrence and progression and prolong patient survival. In some cases, ensidipine may also be used in combination with other treatments (such as chemotherapy) to increase the effectiveness of the treatment.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.